Considering LVI is known to be closely associated with multiple ALN metastases, even in cN0 patients (21, 22), the presence of LVI in a core needle biopsy sample is an important feature that should be included in the standard report to determine the optimal treatment in patients with HR+HER2- breast cancer who have 1–2 suspicious ALNs. This evidence concerns the gene ERBB2 and breast carcinoma.